Roflumilast, a highly effective and specific inhibitor of phosphodiesterase-4 (PDE4), has shown potential in reducing exacerbations in individuals suffering from severe chronic obstructive pulmonary disease (COPD) accompanied by chronic bronchitis or a history of exacerbation (Wedzicha et al., 2016). The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.